Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01395030 · ClinicalTrials.gov registry record · Phase 2
PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
A Phase 2 study, sponsored by Queen's Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT01395030: Completed Phase 2 study, sponsored by Queen's Medical Center.
NCT01395030 is a Phase 2 study that has completed, run by Queen's Medical Center. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01395030, a Phase 2 study, has completed, sponsored by Queen's Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection. Diagnostic procedures, such as fluorine-18 fluoromethylcholine PET/CT, may help find and diagnose liver cancer.
Primary Outcome
Area under the receiver operating characteristic curve for detecting resectable hepatocellular carcinoma with prognostically favorable molecular features (Hoshida molecular sub-class S3) based on FCH PET/CT measurement of tumor maximum standardized uptake value (SUVmax).
Interventions
- DIAGNOSTIC_TEST Computed Tomography
- DIAGNOSTIC_TEST Positron Emission Tomography
- DRUG 18F-fluoromethylcholine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2011-08-15 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 2 |
What the finished NCT01395030 record still lists
NCT01395030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 3 interventions - of which Computed Tomography is the first listed.
NCT01395030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01395030 about?
NCT01395030 is a clinical study titled "PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection". This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection. Diagnostic procedures, such as fluorine-18 fluoromethylcholine PET/CT, may help find and diagnose liver cancer.
What is the current status of trial NCT01395030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2011-08-15. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT01395030?
The interventions under investigation include: Computed Tomography (DIAGNOSTIC_TEST), Positron Emission Tomography (DIAGNOSTIC_TEST), 18F-fluoromethylcholine (DRUG).
Who is sponsoring clinical trial NCT01395030?
This trial is sponsored by Queen's Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01395030's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI